摘要 |
The invention provides GLP-1 compounds coupled to at least one polyethylene glycol molecule or derivative thereof, resulting in a biologically active peptide with an extended half-life and a slower clearance when compared to that of unPEGylated peptide. These PEGylated GLP-1 compounds and compositions are useful in treating diabetes, obesity, irritable bowel syndrome and other conditions that would be benefited by lowering plasma glucose, inhibiting gastric and/or intestinal motility and inhibiting gastric and/or intestinal emptying, or inhibiting food intake. |
申请人 |
ELI LILLY AND COMPANY;DIMARCHI, RICHARD, DENNIS;GLAESNER, WOLFGANG;MILLICAN, ROHN, LEE, JUNIOR;VICK, ANDREW, MARK;ZHANG, LIANSHAN |
发明人 |
DIMARCHI, RICHARD, DENNIS;GLAESNER, WOLFGANG;MILLICAN, ROHN, LEE, JUNIOR;VICK, ANDREW, MARK;ZHANG, LIANSHAN |